Summary There is emerging evidence to support the efficacy of some antiepileptic drug (AED) combinations in refractory epilepsy. Definitive clinical studies are, however, difficult to perform. Experimental seizure models can be employed to identify potentially useful combinations for subsequent clinical evaluation. We have investigated the anticonvulsant effects of topiramate (TPM) in combination with 13 other AEDs in the pentylenetetrazol (PTZ) and maximal electroshock (MES) seizure models. Single drugs and combinations were administered by intraperitoneal injection and anticonvulsant effects determined at 1-hour post-dosing. TPM was without significant effect in the PTZ test. In contrast, phenobarbital, primidone, ethosuximide, sodium valproate, felbamate and tiagabine all increased the latency to the first generalised seizure. Combinations of TPM and active adjunctive drug were universally effective. Combinations of TPM with clobazam, lamotrigine and levetiracetam were also anticonvulsant, despite the inactivity of the constituent compounds when administered alone. TPM reduced the incidence of MES-induced seizures in a dose-dependent manner, as did phenobarbital, phenytoin, primidone, carbamazepine, sodium valproate, clobazam, lamotrigine, felbamate and tiagabine. All combination treatments were similarly effective. These findings suggest that combinations of TPM with lamotrigine and levetiracetam may demonstrate anticonvulsant synergism and merit further investigation in additional model systems and with recourse to more quantitative mathematical analysis.
Introduction
Monotherapy has been the gold standard of antiepileptic drug (AED) treatment for over 20 years 1, 2 . In contrast, polypharmacy has traditionally been fraught with poor tolerability, complicated pharmacokinetic interactions and a greater propensity for cognitive impairment 2, 3 . Recent evidence suggests that monotherapy affords symp-tomatic relief from seizures in only around 60% of people with epilepsy 4 . While a further 3-5% of patients may benefit from combination treatment with two or more AEDs, there remains a significant population of treated patients who continue to experience seizures.
Current wisdom suggests that addressing the problem of refractory epilepsy requires the introduction of novel AEDs, with similarly novel mechanisms of action, for use as monotherapy and the development of a rational approach to treatment which also embraces the potential benefits of polypharmacy. In the last decade of the 20th century, nine new antiepileptic agents reached the global marketplace 5 . Simpler pharmacokinetics, lesser propensity for interactions and more favourable side-effect profiles render them more suitable for use in combination regimens than their predecessors 6, 7 . With this welcome expansion of the pharmacological armamentarium, rational polypharmacy for epilepsy may be a realistic possibility [8] [9] [10] .
Although there is emerging data to endorse the use of some AED combinations in the treatment of refractory epilepsy [11] [12] [13] [14] [15] , definitive evidence supporting efficacy of particular polypharmacy regimens is difficult to obtain. It requires a quantitative assessment of the antiepileptic effect and dose-related side effects of single drugs and combinations in relatively homogeneous populations of epileptic patients. It may be possible to circumvent these difficulties by the use of experimental seizure models to determine the potential protective indices of AED combinations 16 .
Topiramate (TPM) is a contemporary AED with multiple mechanisms of action and efficacy in a wide range of experimental seizure models 17 . Despite limited evidence to support its use in particular polypharmacy regimens 12, [18] [19] [20] , TPM is licensed world-wide as adjunctive treatment for a broad spectrum of seizure types and epilepsy syndromes 5, 21 . In an attempt to identify optimum combinations for further clinical evaluation, we have investigated pharmacodynamic interactions between TPM and a series of traditional and modern AEDs in the pentylenetetrazol (PTZ) and maximal electroshock (MES) seizure models in mice.
Methods

Animals
Adult male ICR mice (25-30 g) were obtained from Harlan Olac (Bicester, UK) and housed in a controlled temperature and humidity environment with day/night cycle conditions and access to food and water ad libitum. Animals were kept for a minimum period of 7 days prior to use to allow for acclimatisation. All experimental work was governed by the Animals (Scientific Procedures) Act, 1986 (UK).
Reagents
All chemicals (reagent grade), PTZ, and the established AEDs, phenobarbital (5-ethyl-5-phenyl-2,4, 6-trioxohexahydropyrimidine), phenytoin (5,5- 
Drug administration
All drugs were prepared daily for intraperitoneal (i.p.) injection. Phenobarbital, phenytoin, primidone, carbamazepine and TPM were prepared as a suspension in 0.5% Tween 80 (polyoxyethylene sorbitan monooleate). Felbamate was suspended in 30% polyethylene glycol 400. All other agents were dissolved in 0.9% saline.
Study design
All experiments were designed to include a control group, three single dose TPM groups (5, 25 and 125 mg/kg), three single dose adjunctive drug groups (low, medium and high dose) and nine further groups encompassing all possible combinations Drug X = adjunctive drug (see Table 2 for appropriate doses). of TPM and adjunctive drug (Tables 1 and 2 ). PTZ studies employed six mice per treatment group, while MES studies used 10 animals per group.
Pentylenetetrazol test
At 1-hour post-dosing, mice were administered 85 mg/kg PTZ (37 • C; in 0.9% saline) by subcutaneous (s.c.) injection and the time to the first generalised seizure with loss of the righting reflex was recorded in individual animals 22 . Experiments were conducted in a blinded manner (observers; GGT & EB). An arbitrary cut-off time of 15 minutes was assigned for non-responsive animals.
Maximal electroshock test
At 1-hour post-dosing, mice were subjected to the MES test 22 . Constant current electroshock stimuli were delivered via auricular electrodes from an ECT unit (Ugo Basile 7800, Comerio, Italy). MES stimuli, comprising 0.2 seconds of rectangular positive pulses (50 mA at 60 Hz; pulse width = 0.4 milliseconds), were pre-determined to induce 100% tonic seizures in a group of naïve animals. The percentage of animals exhibiting tonic hind-limb extension in each treatment group was recorded. Experiments were again conducted in a blinded manner (observer; GGT).
Statistical analysis
Analysis was performed using MINITAB for Windows statistical package (Version 10.1) on a Viglen Contender ATX P5/166 MMX microcomputer. PTZ seizure data were expressed as the mean time (seconds) to the first generalised seizure in each treatment group and compared to control by one-way ANOVA with a Dunnett correction for multiple comparisons. MES seizure data were expressed as the percentage of animals exhibiting tonic hind-limb extension in each treatment group and compared to control with Fisher's exact test using a Bonferroni correction for multiple comparisons.
Results
Pentylenetetrazol studies
In the PTZ studies, TPM was without anticonvulsant effect (Table 3) . Of the adjunctive agents investigated, single doses of phenobarbital, primidone, ethosuximide, sodium valproate, felbamate and tiagabine all significantly (P < 0.05) increased the latency to PTZ-induced seizures when compared to control (Table 3) . When combined with TPM, these active agents were similarly effective ( Table 3) . Combinations of TPM with clobazam ( Fig. 1) , lamotrigine ( Fig. 2) and levetiracetam ( Fig. 3 ) afforded significant (P < 0.05) protection against PTZ-induced seizures, despite inactivity of the constituent agents when administered alone.
Maximal electroshock studies
In the MES studies, TPM significantly (P < 0.05) reduced the incidence of tonic hind-limb extension when compared to control (Table 4) . Of the adjunctive agents investigated, single doses of Table 3 The latency to the first generalised seizure induced by 85 mg/kg PTZ at 1 hour after treatment with TPM and/or adjunctive drug (see Tables 1 and 2 for definition of treatment groups) in groups (n = 6) of mice. phenobarbital, phenytoin, primidone, carbamazepine, sodium valproate, clobazam, lamotrigine, felbamate and tiagabine significantly (P < 0.05) protected against MES-induced seizures (Table 4 ). All combination treatments were effective in the MES model (Table 4 ). 
Discussion
Although new AEDs are almost exclusively introduced as adjunctive treatment, there is only limited evidence to support the use of specific drug combinations 13 . In the absence of convincing clini- cal data, experimental seizure models can be employed to identify potentially useful polypharmacy regimens for further patient-based evaluation 16 . We have explored potential pharmacodynamic interactions between TPM and a number of traditional and contemporary AEDs in the PTZ and MES seizure models. In keeping with previous investigations 17, 18 , single dose TPM was without effect on the latency to PTZ-induced seizures. In contrast, several adjunctive agents including phenobarbital, primidone, ethosuximide, sodium valproate, felbamate and tiagabine all had significant anticonvulsant effects when administered alone. These findings were anticipated on the basis of prior studies [23] [24] [25] , although the inactivity of clobazam in the PTZ model was unexpected. Combinations of TPM with active adjunctive agents were universally effective, suggesting the absence of any infra-additive efficacy. Furthermore, when TPM was combined with clobazam, lamotrigine and levetiracetam, anticonvulsant effects in the PTZ model were observed, despite the inactivity of the constituent compounds.
Anticonvulsant synergism with combinations of TPM and lamotrigine in the PTZ model has been reported previously 12 , although the basis for this apparent interaction remains unclear. TPM is active in the PTZ threshold test 25 , and while neither TPM nor lamotrigine is sufficiently powerful to prevent supra-maximal PTZ seizures when administered alone, their combined efficacy on seizure threshold may provide otherwise obscured protection. A similar situation may prevail when TPM is combined with levetiracetam, which like TPM has no recognised efficacy in the supra-maximal PTZ test, but does elevate the PTZ seizure threshold 26 . In both cases, however, pharmacokinetic interaction cannot be ruled out, although none would be anticipated on the basis of published data 6 . The evidence for synergism between TPM and clobazam is considerably less convincing, given the widely recognised efficacy of benzodiazepines in the PTZ model 23 . While it is possible that the addition of TPM, even at the lowest dose, helped unmask the anticipated activity of clobazam, it is difficult to reconcile this relative insensitivity in a series of PTZ studies which otherwise followed convention in terms of AED efficacy.
In the MES model, TPM produced a dose-dependent reduction in the incidence of tonic seizures when administered alone. This finding was consistent with those of previous investigations 17, 18 . The majority of adjunctive treatments, with the exception of ethosuximide, vigabatrin, gabapentin and levetiracetam, also had protective effects against MES-induced seizures following single dose administration. Again, these observations were largely as expected [23] [24] [25] , although the activity of tiagabine in the MES test is not widely reported 27 . Table 4 The incidence of tonic hind-limb extension induced by MES at 1 hour after treatment with TPM and/or adjunctive drug (see Tables 1 and 2 for definition of treatment groups) in groups (n = 10) of mice. With the efficacy of TPM, and a preponderance of active compounds, combination treatment in the MES model was universally effective. Accordingly, this arm of the investigation revealed little with regard to potential pharmacodynamic interactions, although it did again suggest the absence of antagonism or infra-additive efficacy between TPM and other active agents.
Although this investigation revealed few positive or unanticipated results, there is emerging experimental evidence to support the efficacy of particular combinations of established and new AEDs. Isobolographic analysis has revealed potential synergism between gabapentin and a variety of agents 28 and a specific interaction between oxcarbazepine and clonazepam 29 . A further study in the 4-aminopyridine model has suggested potential benefits of combining felbamate and lamotrigine 30 . These investigations employed measures of both efficacy and toxicity and incorporated drug analysis to eliminate the potential interference of pharmacokinetic interactions. Similarly detailed studies with TPM have been reported 19, 20 . Sub-effective doses of TPM potentiated the anticonvulsant effects of phenobarbital, phenytoin and sodium valproate in the MES model without increasing toxicity or influencing AED pharmacokinetics 19 . Further investigations with TPM identified a pharmacodynamic interaction with phenobarbital and sodium valproate in the amygdala-kindled rat and with ethosuximide in the PTZ test 20 .
In the interests of simplicity, the current study relied on the subjective assessment of pharmacodynamic interactions, without recourse to detailed mathematical analysis of the data. As such, the findings were compromised when one or both constituent compounds was active in the chosen model. This was particularly evident in the MES test where TPM was effective and, accordingly, all combinations were effective. The probability of identifying supra-additive or synergistic combinations was therefore limited and, in most cases, interactions could be regarded as no more than additive. Furthermore, without conducting a concurrent investigation of the potential neurotoxicity of combination treatments or ruling out the potential interference of pharmacokinetic interactions, it is difficult to ascribe true pharmacodynamic synergism to any of the combination treatments assessed. Finally, with the use of acute drug administration and a groundswell of opinion which suggests that the PTZ and MES models are not sufficiently representative of the clinical condition, the impact of this investigation may be limited without further investigation.
In conclusion, this study investigated pharmacodynamic interactions between TPM and a number of traditional and contemporary AEDs as an antecedent to identifying candidate drug combinations in the laboratory without resorting to complex, expensive and time-consuming clinical screening. The study design and model systems employed did not facilitate sufficient discrimination between positive results and, in the majority of cases, interactions could be regarded as additive at best. However, despite additional shortcomings common to many pre-clinical studies, specific combinations of TPM with lamotrigine and levetiracetam were identified and these clearly merit further detailed investigation for the treatment of refractory epilepsy.
